Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01828008

Acronym

CIK

Enrollment

Registered

2013-04-10

Start date

2013-04-30

Completion date

2015-05-31

Last updated

2013-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphomas

Keywords

Mabthera, cytokine induced killer cell

Brief summary

To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Detailed description

Autologous CIK transfusion within 3 days post CD20 antibody treatment.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

\- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy

Exclusion criteria

\- to refuse the therapy and need not tolerate the therapy

Design outcomes

Primary

Measure	Time frame
disease free survival	5 years

Outcome results